Arya Sciences II (ARYB) to Combine with Cerevel Therapeutics

Arya Sciences Acquisition Corp. II (ARYB), announced this morning that they have entered into a definitive business combination agreement with Cerevel Therapeutics, Inc. (“Cerevel Therapeutics”), a company dedicated to treating neuroscience diseases. This transaction is expected to have an initial market capitalization of approximately $1.3 billion, with an implied enterprise value of $847.4 million. In
Read More